Pharmaceuticals
GN Corporation and Edogawa Evolutionary Laboratory of Science Cosponsor International Academic Conference, NCRM NICHE 2019, on October 15, 2019
KOFU, Japan and TOKYO, Oct. 21, 2019 /PRNewswire/ -- GN Corporation Co., Ltd., a Japanese firm involved in research and development of technology in regenerative medicine, and Edogawa Evolutionary Laboratory of Science(EELS), a unit ofTokyo's Edogawa Hospital, cosponsored NCRM NICHE 2019 (www.ncr...
2019-10-21 14:00
204
Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
AUSTIN, Texas, Oct. 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that Dr. Heather Wilson-Robles DVM, DACVIM, Associate Professor and Dr. Fred and Vola N. Palmer Chair in Comparative Oncology, Texas A&M College of Veterinary Medicine & Biomedical S...
2019-10-18 20:30
3448
China Biologic Special Committee Retains Financial Advisor and Legal Counsel
BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...
2019-10-17 20:00
4136
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
SHANGHAI, Oct. 16, 2019 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage drug discovery and development company which devotes its efforts towards discovering, developing and delivering innovative medicines that help patients prevail over liver diseases, announced today that it has dos...
2019-10-16 18:00
181
Collaborative Medicinal Development Enrolls First Patient In a Randomized, Placebo-Controlled Clinical Trial of CuATSM For The Treatment of Amyotrophic Lateral Sclerosis
MILL VALLEY, Calif. and MELBOURNE, Australia, Oct. 15, 2019 /PRNewswire/ -- Collaborative Medicinal Development, LLC) ("CMD"), a clinical stage biopharmaceutical company with a portfolio of candidates for treatment of neurological and neuropsychiatric diseases, announced today that it enrolled t...
2019-10-15 05:58
290
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal
SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients inAustralia, New Zealand and throughout SE Asia. Under the ...
2019-10-14 14:00
251
Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.
SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...
2019-10-11 13:00
341
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...
2019-10-04 13:40
502
Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine
QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...
2019-10-03 06:30
387
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US
ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...
2019-10-02 12:01
7532
Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval
SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...
2019-10-01 04:00
7022
Yuyu Pharma Unveils New Corporate Logo
SEOUL, South Korea, Sept. 30, 2019 /PRNewswire/ -- Yuyu's corporate logo was
first created in 1941 to honor the company's proud history and highlight Yuyu's
image as a company on the cutting-edge of the industry.
2019-09-30 21:00
282
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
2019-09-30 16:30
252
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019
NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...
2019-09-30 13:41
220
The 10th China (Taizhou) International Medical Expo successfully ended
NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th
China (Taizhou) International Medical Expo was held in China Medical City
(CMS), according toChina (Taizhou) Medical Expo News Center.
2019-09-30 13:27
253
Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019
* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...
2019-09-30 06:00
304
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...
2019-09-30 05:00
285
China Biologic Forms Special Committee to Review "Going Private" Proposal
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...
2019-09-24 20:00
11265
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, today annou...
2019-09-23 19:00
862
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) eligibility to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation ...
2019-09-23 18:00
1708
Week's Top Stories
Most Reposted
ZTE and China Unicom win Best Network Intelligence Award at Broadband Awards 2019
[Picked up by 115 media titles]
2019-10-17 17:01
ZTE wins 5G Excellence Award at the SDN/NFV World Congress
[Picked up by 103 media titles]
2019-10-17 15:32
The Fullerton Hotel Sydney Debuts at No.1 Martin Place
[Picked up by 101 media titles]
2019-10-17 21:01Xinhua Silk Road: CEIS, Fitch Solutions jointly release report on opportunities in ASEAN under BRI
[Picked up by 96 media titles]
2019-10-17 09:10
Goodbaby Launched New Products Designed by Dutch Illustrator Rick Berkelmans in Celebration of its 30th Anniversary
[Picked up by 93 media titles]
2019-10-18 21:59
Most Read
Far East Hospitality Rethinks Luxury With the Launch of The Clan Hotel
2019-10-17 18:15
9636
Vinamilk impresses Chinese consumers with a wide range of high-quality dairy products
2019-10-17 10:45
7483
Infineon's New microcontroller optimized for automotive 77 GHz radar applications
2019-10-16 13:57
5122
